dc.contributor
Institut Català de la Salut
dc.contributor
[Mosele MF] INSERM U981, Gustave Roussy, Villejuif, France. Department of Cancer Medicine, Gustave Roussy, Villejuif, France. [Westphalen CB] Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Germany. [Stenzinger A] Institute of Pathology, University Hospital Heidelberg and Center for Personalized Medicine (ZPM), Heidelberg, Germany. [Barlesi F] INSERM U981, Gustave Roussy, Villejuif. Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre. [Bayle A] Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre. Drug Development Department (DITEP), Gustave Roussy, Villejuif. Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif. Service de Biostatistique et Epidémiologie, Gustave Roussy, Villejuif. [Bièche I] Department of Genetics, Institut Curie, INSERM U1016, Université Paris Cité, Paris, France. [Dienstmann R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic—Central University of Catalonia, Vic, Spain. University of Vic—Central University of Catalonia, Vic, Spain. Oncoclínicas, São Paulo, Brazil. [Serrano C, Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Mosele, Maria
dc.contributor.author
Stenzinger, Albrecht
dc.contributor.author
Bayle, Arnaud
dc.contributor.author
Bieche, Ivan
dc.contributor.author
Westphalen, Benedikt
dc.contributor.author
Barlesi, Fabrice
dc.contributor.author
Dienstmann, Rodrigo
dc.contributor.author
Serrano, Cesar
dc.contributor.author
Mateo, Joaquin
dc.date.accessioned
2025-10-25T05:38:10Z
dc.date.available
2025-10-25T05:38:10Z
dc.date.issued
2024-06-27T09:56:38Z
dc.date.issued
2024-06-27T09:56:38Z
dc.identifier
Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024 Jul;35(7):588–606.
dc.identifier
https://hdl.handle.net/11351/11639
dc.identifier
10.1016/j.annonc.2024.04.005
dc.identifier.uri
http://hdl.handle.net/11351/11639
dc.description.abstract
Advanced cancer; Next-generation sequencing; Precision medicine
dc.description.abstract
Càncer avançat; Seqüenciació de nova generació; Medicina de precisió
dc.description.abstract
Cáncer avanzado; Secuenciación de nueva generación; Medicina de precisión
dc.description.abstract
Background
Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice.
Methods
The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility.
Results
As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer. Moreover, it is recommended to carry out tumour NGS in clinical research centres and under specific circumstances discussed with patients. In this updated report, the consensus within the group has led to an expansion of the recommendations to encompass patients with advanced breast cancer and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary. Finally, ESMO recommends carrying out tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available.
Conclusion
Tumour NGS is increasingly expanding its scope and application within oncology with the aim of enhancing the efficacy of precision medicine for patients with cancer.
dc.description.abstract
This project was funded by the European Society for Medical Oncology (no grant numbers are applicable).
dc.format
application/pdf
dc.relation
Annals of Oncology;35(7)
dc.relation
https://doi.org/10.1016/j.annonc.2024.04.005
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicina personalitzada
dc.subject
Càncer - Tractament
dc.subject
Càncer - Aspectes genètics
dc.subject
Seqüència de nucleòtids
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Genetic Techniques::Sequence Analysis::High-Throughput Nucleotide Sequencing
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::/therapy
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas genéticas::análisis de secuencias::secuenciación de nucleótidos de alto rendimiento
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::/terapia
dc.title
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
